#AACR20 roundup: Tecen­triq/Xtan­di com­bo fails to show OS ben­e­fit, halt­ing Roche's PD-L1 push in­to prostate can­cer

For the first time in its 100-year-plus his­to­ry, the Amer­i­can As­so­ci­a­tion for Can­cer Re­search is host­ing its an­nu­al meet­ing com­plete­ly on­line. Here’s a glance at some of the ab­stracts — which dropped ear­ly Mon­day — mak­ing the rounds:

Roche con­ced­ed that Tecen­triq failed to help prostate can­cer pa­tients live longer when added to Xtan­di, Pfiz­er and Astel­las’ main­stay an­dro­gen re­cep­tor an­tag­o­nist. The Phase III study dubbed IM­bas­sador en­rolled 759 pa­tients with metasta­t­ic cas­tra­tion-re­sis­tant prostate can­cer who had been treat­ed with one pri­or line of chemother­a­py and had pro­gressed af­ter tak­ing an­dro­gen syn­the­sis in­hibitors.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER